Research programme: hyperuricaemia therapies - Nippon Chemiphar
Latest Information Update: 19 Jul 2016
At a glance
- Originator Nippon Chemiphar
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Hyperuricaemia
Highest Development Phases
- Research Hyperuricaemia
Most Recent Events
- 19 Jul 2016 Early research in Hyperuricaemia in Japan (unspecified route)
- 19 Jul 2016 Research programme: hyperuricaemia therapies - Nippon Chemiphar is available for licensing as of 19 Jul 2016. http://www.chemiphar.co.jp/